S&P 500   3,822.82 (-0.17%)
DOW   31,014.65 (-1.23%)
QQQ   316.30 (+1.11%)
AAPL   123.21 (+1.83%)
MSFT   233.40 (+1.93%)
FB   262.23 (+2.96%)
GOOGL   2,033.50 (+0.87%)
AMZN   3,081.08 (+0.78%)
TSLA   675.53 (-0.98%)
NVDA   548.14 (+2.98%)
BABA   240.74 (+0.23%)
CGC   32.56 (-1.96%)
GE   12.68 (-0.63%)
MU   91.71 (+4.07%)
NIO   46.49 (-0.68%)
AMD   84.43 (+2.44%)
T   28.03 (-2.10%)
F   11.77 (+0.09%)
ACB   10.71 (-1.02%)
DIS   189.64 (-0.70%)
BA   212.48 (-1.83%)
NFLX   542.98 (-0.68%)
BAC   34.93 (-2.78%)
S&P 500   3,822.82 (-0.17%)
DOW   31,014.65 (-1.23%)
QQQ   316.30 (+1.11%)
AAPL   123.21 (+1.83%)
MSFT   233.40 (+1.93%)
FB   262.23 (+2.96%)
GOOGL   2,033.50 (+0.87%)
AMZN   3,081.08 (+0.78%)
TSLA   675.53 (-0.98%)
NVDA   548.14 (+2.98%)
BABA   240.74 (+0.23%)
CGC   32.56 (-1.96%)
GE   12.68 (-0.63%)
MU   91.71 (+4.07%)
NIO   46.49 (-0.68%)
AMD   84.43 (+2.44%)
T   28.03 (-2.10%)
F   11.77 (+0.09%)
ACB   10.71 (-1.02%)
DIS   189.64 (-0.70%)
BA   212.48 (-1.83%)
NFLX   542.98 (-0.68%)
BAC   34.93 (-2.78%)
S&P 500   3,822.82 (-0.17%)
DOW   31,014.65 (-1.23%)
QQQ   316.30 (+1.11%)
AAPL   123.21 (+1.83%)
MSFT   233.40 (+1.93%)
FB   262.23 (+2.96%)
GOOGL   2,033.50 (+0.87%)
AMZN   3,081.08 (+0.78%)
TSLA   675.53 (-0.98%)
NVDA   548.14 (+2.98%)
BABA   240.74 (+0.23%)
CGC   32.56 (-1.96%)
GE   12.68 (-0.63%)
MU   91.71 (+4.07%)
NIO   46.49 (-0.68%)
AMD   84.43 (+2.44%)
T   28.03 (-2.10%)
F   11.77 (+0.09%)
ACB   10.71 (-1.02%)
DIS   189.64 (-0.70%)
BA   212.48 (-1.83%)
NFLX   542.98 (-0.68%)
BAC   34.93 (-2.78%)
S&P 500   3,822.82 (-0.17%)
DOW   31,014.65 (-1.23%)
QQQ   316.30 (+1.11%)
AAPL   123.21 (+1.83%)
MSFT   233.40 (+1.93%)
FB   262.23 (+2.96%)
GOOGL   2,033.50 (+0.87%)
AMZN   3,081.08 (+0.78%)
TSLA   675.53 (-0.98%)
NVDA   548.14 (+2.98%)
BABA   240.74 (+0.23%)
CGC   32.56 (-1.96%)
GE   12.68 (-0.63%)
MU   91.71 (+4.07%)
NIO   46.49 (-0.68%)
AMD   84.43 (+2.44%)
T   28.03 (-2.10%)
F   11.77 (+0.09%)
ACB   10.71 (-1.02%)
DIS   189.64 (-0.70%)
BA   212.48 (-1.83%)
NFLX   542.98 (-0.68%)
BAC   34.93 (-2.78%)
Log in
NASDAQ:FIXX

Homology Medicines News Headlines

$10.46
-0.38 (-3.51 %)
(As of 02/26/2021 02:15 PM ET)
Add
Compare
Today's Range
$10.30
Now: $10.46
$11.05
50-Day Range
$11.22
MA: $12.97
$14.80
52-Week Range
$8.70
Now: $10.46
$22.38
Volume22,987 shs
Average Volume333,320 shs
Market Capitalization$473.46 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.24

Headlines

Homology Medicines (NASDAQ FIXX) News Headlines Today

Source:
SourceHeadline
Homology Medicines to Participate in Upcoming Investor and Patient Advocacy ConferencesHomology Medicines to Participate in Upcoming Investor and Patient Advocacy Conferences
finance.yahoo.com - February 25 at 9:44 AM
What Type Of Shareholders Own The Most Number of Homology Medicines, Inc. (NASDAQ:FIXX) Shares?What Type Of Shareholders Own The Most Number of Homology Medicines, Inc. (NASDAQ:FIXX) Shares?
finance.yahoo.com - February 19 at 9:07 AM
Homology Medicines (NASDAQ:FIXX)  Shares Down 11.7% Homology Medicines (NASDAQ:FIXX) Shares Down 11.7%
americanbankingnews.com - February 18 at 9:16 PM
Homology Medicines (NASDAQ:FIXX) Stock Price Up 7.4%Homology Medicines (NASDAQ:FIXX) Stock Price Up 7.4%
americanbankingnews.com - February 8 at 9:08 PM
Homology Medicines Announces First Presentation of Data with HMI-203 In Vivo Gene Therapy Development Candidate for Hunter SyndromeHomology Medicines Announces First Presentation of Data with HMI-203 In Vivo Gene Therapy Development Candidate for Hunter Syndrome
finance.yahoo.com - February 8 at 3:03 PM
Homology Medicines, Inc. (NASDAQ:FIXX) Sees Significant Decrease in Short InterestHomology Medicines, Inc. (NASDAQ:FIXX) Sees Significant Decrease in Short Interest
americanbankingnews.com - February 3 at 9:58 AM
Homology Medicines Inc.Homology Medicines Inc.
barrons.com - January 9 at 11:42 PM
Homology Medicines Announces Plans for Three Clinical Programs in 2021 Spanning Phenylketonuria (PKU) and Hunter Syndrome (MPS II)Homology Medicines Announces Plans for Three Clinical Programs in 2021 Spanning Phenylketonuria (PKU) and Hunter Syndrome (MPS II)
finance.yahoo.com - January 6 at 9:59 AM
Alexion, Calyxt, Arvinas: 5 Top Stock Gainers for MondayAlexion, Calyxt, Arvinas: 5 Top Stock Gainers for Monday
finance.yahoo.com - December 14 at 2:19 PM
Is FIXX A Good Stock To Buy Now?Is FIXX A Good Stock To Buy Now?
finance.yahoo.com - December 12 at 12:02 AM
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Homology Medicines (FIXX) Investors with Losses to Contact Its Attorneys,HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Homology Medicines (FIXX) Investors with Losses to Contact Its Attorneys,
bloomberg.com - November 11 at 10:08 AM
Homology Medicines Reports Third Quarter 2020 Financial Results and Recent HighlightsHomology Medicines Reports Third Quarter 2020 Financial Results and Recent Highlights
finance.yahoo.com - November 9 at 5:44 PM
Homology Medicines nabs investment from PfizerHomology Medicines nabs investment from Pfizer
seekingalpha.com - November 9 at 12:44 PM
Reflecting on Homology Medicines (NASDAQ:FIXX) Share Price Returns Over The Last YearReflecting on Homology Medicines' (NASDAQ:FIXX) Share Price Returns Over The Last Year
finance.yahoo.com - November 8 at 2:41 PM
Homology Medicines slumps on gene therapy data in inherited metabolic disorderHomology Medicines slumps on gene therapy data in inherited metabolic disorder
seekingalpha.com - November 6 at 7:36 PM
Homology Medicines Announces Presentation of Positive Data from the Dose-Escalation Phase of the pheNIX Gene Therapy Trial for Adults with PKUHomology Medicines Announces Presentation of Positive Data from the Dose-Escalation Phase of the pheNIX Gene Therapy Trial for Adults with PKU
finance.yahoo.com - November 6 at 2:35 PM
Homology Medicines Announces Upcoming Oral Presentation on pheNIX Gene Therapy Clinical Trial for Adults with PKUHomology Medicines Announces Upcoming Oral Presentation on pheNIX Gene Therapy Clinical Trial for Adults with PKU
finance.yahoo.com - November 5 at 1:32 PM
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Homology Medicines (FIXX) Investors with Losses to Contact Its Attorneys, Investigation into Possible Securities Fraud OngoingHAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Homology Medicines (FIXX) Investors with Losses to Contact Its Attorneys, Investigation into Possible Securities Fraud Ongoing
finance.yahoo.com - October 29 at 6:54 PM
FIXX SHAREHOLDER ALERT: Hagens Berman, National Trial Attorneys, Encourages Homology Medicines (FIXX) Investors with Losses to Contact Its Attorneys, Firm Investigating Possible Securities FraudFIXX SHAREHOLDER ALERT: Hagens Berman, National Trial Attorneys, Encourages Homology Medicines (FIXX) Investors with Losses to Contact Its Attorneys, Firm Investigating Possible Securities Fraud
finance.yahoo.com - October 27 at 7:01 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Homology Medicines, Inc. – FIXXSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Homology Medicines, Inc. – FIXX
benzinga.com - October 26 at 11:38 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Homology Medicines, Inc. – FIXXSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Homology Medicines, Inc. – FIXX
finance.yahoo.com - October 26 at 11:38 PM
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Updates FIXX, TILE Investors, Encourages Investors with Losses to Contact Its Attorneys, Securities Fraud Investigations OngoingHAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Updates FIXX, TILE Investors, Encourages Investors with Losses to Contact Its Attorneys, Securities Fraud Investigations Ongoing
finance.yahoo.com - October 26 at 6:37 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims  On Behalf of Investors of Homology Medicines, Inc. - FIXXSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Homology Medicines, Inc. - FIXX
finance.yahoo.com - October 23 at 11:12 PM
Homology Medicines unveils gene therapy program for rare metabolic disorderHomology Medicines unveils gene therapy program for rare metabolic disorder
seekingalpha.com - October 22 at 7:36 PM
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Homology Medicines, Inc. and Encourages Investors with Losses of $100,000 to Contact the FirmINVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Homology Medicines, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm
finance.yahoo.com - October 22 at 7:36 PM
Homology Medicines unveils gene therapy program targeting rare metabolic disorderHomology Medicines unveils gene therapy program targeting rare metabolic disorder
seekingalpha.com - October 22 at 2:35 PM
Homology Medicines Unveils New In Vivo Gene Therapy Development Program for Hunter SyndromeHomology Medicines Unveils New In Vivo Gene Therapy Development Program for Hunter Syndrome
finance.yahoo.com - October 22 at 9:35 AM
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Homology Medicines, Inc. and Encourages Investors with Losses of $100,000 to Contact the FirmONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Homology Medicines, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm
finance.yahoo.com - October 21 at 12:47 PM
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Homology Medicines, Inc. and Encourages Investors with Losses of $100,000 to Contact the FirmSHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Homology Medicines, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm
finance.yahoo.com - October 20 at 9:27 AM
FIXX INVESTOR FRAUD: Hagens Berman, National Trial Attorneys, Encourages Homology Medicines (FIXX) Investors with Losses to Contact Its Attorneys, Firm Investigating Possible Securities FraudFIXX INVESTOR FRAUD: Hagens Berman, National Trial Attorneys, Encourages Homology Medicines (FIXX) Investors with Losses to Contact Its Attorneys, Firm Investigating Possible Securities Fraud
finance.yahoo.com - October 17 at 6:43 PM
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Homology Medicines (FIXX) Investors with Losses to Contact Its Attorneys, FHAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Homology Medicines (FIXX) Investors with Losses to Contact Its Attorneys, F
bloomberg.com - October 10 at 5:21 PM
Homology Medicines to Participate in Upcoming ConferencesHomology Medicines to Participate in Upcoming Conferences
finance.yahoo.com - September 18 at 1:25 PM
Stock Alert: Homology Medicines Declines 11% On Q2 ResultsStock Alert: Homology Medicines Declines 11% On Q2 Results
nasdaq.com - August 11 at 4:14 PM
Homology Medicines EPS misses by $0.02, revenue in-lineHomology Medicines EPS misses by $0.02, revenue in-line
seekingalpha.com - August 10 at 8:31 PM
Were Keeping An Eye On Homology Medicines (NASDAQ:FIXX) Cash Burn RateWe're Keeping An Eye On Homology Medicines' (NASDAQ:FIXX) Cash Burn Rate
finance.yahoo.com - August 10 at 8:31 PM
Homology Medicines Reports Second Quarter 2020 Financial Results and Provides Business UpdateHomology Medicines Reports Second Quarter 2020 Financial Results and Provides Business Update
finance.yahoo.com - August 10 at 8:31 PM
Homology Medicines (FIXX) Reports Q2 Loss, Tops Revenue EstimatesHomology Medicines (FIXX) Reports Q2 Loss, Tops Revenue Estimates
finance.yahoo.com - August 10 at 8:31 PM
Heres Why Were Watching Homology Medicines (NASDAQ:FIXX) Cash Burn SituationHere's Why We're Watching Homology Medicines' (NASDAQ:FIXX) Cash Burn Situation
finance.yahoo.com - August 10 at 3:24 PM
Here's Why We're Watching Homology Medicines' (NASDAQ:FIXX) Cash Burn SituationHere's Why We're Watching Homology Medicines' (NASDAQ:FIXX) Cash Burn Situation
finance.yahoo.com - August 10 at 3:24 PM
We're Keeping An Eye On Homology Medicines' (NASDAQ:FIXX) Cash Burn RateWe're Keeping An Eye On Homology Medicines' (NASDAQ:FIXX) Cash Burn Rate
finance.yahoo.com - August 10 at 3:24 PM
Earnings Preview: Homology Medicines (FIXX) Q2 Earnings Expected to DeclineEarnings Preview: Homology Medicines (FIXX) Q2 Earnings Expected to Decline
finance.yahoo.com - August 6 at 2:50 PM
Homology Medicines Appoints Jeff Poulton to the Board of DirectorsHomology Medicines Appoints Jeff Poulton to the Board of Directors
finance.yahoo.com - July 21 at 12:48 PM
Homology Medicines (FIXX) Looks Good: Stock Adds 8% in SessionHomology Medicines (FIXX) Looks Good: Stock Adds 8% in Session
finance.yahoo.com - July 8 at 9:49 AM
Homology Medicines, Inc. (FIXX): Hedge Funds Are Snapping UpHomology Medicines, Inc. (FIXX): Hedge Funds Are Snapping Up
finance.yahoo.com - June 27 at 6:41 PM
Homology Medicines Announces Peer-Reviewed Publication of HMI-102 Investigational Gene Therapy Demonstrating Restoration ofHomology Medicines Announces Peer-Reviewed Publication of HMI-102 Investigational Gene Therapy Demonstrating Restoration of
www.bloomberg.com - June 16 at 5:29 PM
Homology Medicines Announces Peer-Reviewed Publication Describing Molecular Characterization of Precise In Vivo Nuclease-Free Gene Editing with PKU ProgramHomology Medicines Announces Peer-Reviewed Publication Describing Molecular Characterization of Precise In Vivo Nuclease-Free Gene Editing with PKU Program
finance.yahoo.com - May 26 at 3:00 PM
Homology Medicines Announces Presentations on its In Vivo Gene Therapy and Gene Editing Programs and Commercial Manufacturing Platform at the American Society of Gene & Cell Therapy Annual MeetingHomology Medicines Announces Presentations on its In Vivo Gene Therapy and Gene Editing Programs and Commercial Manufacturing Platform at the American Society of Gene & Cell Therapy Annual Meeting
finance.yahoo.com - May 12 at 9:07 AM
Homology Medicines, Inc. (NASDAQ:FIXX) Consensus Forecasts Have Become A Little Darker Since Its Latest ReportHomology Medicines, Inc. (NASDAQ:FIXX) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
finance.yahoo.com - May 10 at 4:00 PM
Homology Medicines Reports First Quarter 2020 Financial Results and Recent HighlightsHomology Medicines Reports First Quarter 2020 Financial Results and Recent Highlights
finance.yahoo.com - May 7 at 11:30 PM
Homology Medicines EPS misses by $0.09, beats on revenueHomology Medicines EPS misses by $0.09, beats on revenue
seekingalpha.com - May 7 at 6:30 PM
This page was last updated on 2/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.